Tag: aducanumab

Shares of biotech company Biogen were soaring on Monday after Wall Street learned that the Food & Drug Administration has approved the company’s Alzheimer’s drug. The drug, called aducanumab, is the first new therapy for Alzheimer’s Disease in nearly two decades and Aducanumab is the first drug cleared by U.S. regulators to slow cognitive decline … Continue reading “Biogen Shares Explode on FDA Approval of Alzheimer’s Drug”